MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Evaluation of BIS for Quantification of Lymphedema

Completed

Conditions: Breast Cancer

Interventions: Other: Bioimpedance Spectroscopy

First Posted Date: 2012-03-05

Last Posted Date: 2024-06-27

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 270

Registration Number: NCT01544335

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

EEG Studies of Induction and Recovery From Propofol Induced General Anesthesia

Not Applicable

Completed

Conditions: Brain Activity Under Sedation

Interventions: Drug: Propofol

First Posted Date: 2012-03-05

Last Posted Date: 2022-01-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 36

Registration Number: NCT01543633

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Two Stepped Care Models for Posttraumatic Stress Disorder (PTSD) Among Cambodian Refugees With PTSD

Phase 4

Terminated

Conditions: Posttraumatic Stress Disorder (PTSD)

Interventions: Drug: Medication augmentation
Behavioral: CBT

First Posted Date: 2012-03-02

Last Posted Date: 2017-05-17

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 114

Registration Number: NCT01542372

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Normobaric Oxygen (NBO) Therapy in Acute Migraine

Phase 2

Completed

Conditions: Migraine

Interventions: Biological: Oxygen
Biological: Room air

First Posted Date: 2012-03-02

Last Posted Date: 2017-03-27

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 22

Registration Number: NCT01542307

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

The Effect of Vitamin C on Growth Hormone Secretion

Phase 2

Withdrawn

Conditions: Obese
Disorder of Vitamin C
Growth Hormone Secretion Abnormality

Interventions: Dietary Supplement: Placebo
Dietary Supplement: Vitamin C 250 mg once daily
Dietary Supplement: Vitamin C 1,000 mg once daily

First Posted Date: 2012-02-23

Last Posted Date: 2013-12-13

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT01537094

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Not Applicable

Completed

Conditions: Papillary Thyroid Carcinoma

Interventions: Drug: GSK2118436

First Posted Date: 2012-02-17

Last Posted Date: 2017-03-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 10

Registration Number: NCT01534897

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Phase 2

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Adriamycin, vinblastine, and dacarbazine

First Posted Date: 2012-02-16

Last Posted Date: 2018-02-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 34

Registration Number: NCT01534078

Locations: 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

Not Applicable

Completed

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Executive Function Deficits (EFD)

Interventions: Drug: Placebo
Drug: Memantine Hydrochloride
Drug: OROS-Methylphenidate

First Posted Date: 2012-02-15

Last Posted Date: 2014-04-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 33

Registration Number: NCT01533493

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Midodrine for the Treatment of Refractory Hypotension

Phase 3

Completed

Conditions: Critical Illness
Hypotension

Interventions: Drug: Placebo
Drug: Midodrine

First Posted Date: 2012-02-13

Last Posted Date: 2020-10-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 139

Registration Number: NCT01531959

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

Phase 2

Completed

Conditions: Blood Transfusion
Nitric Oxide
Endothelial Physiopathology
Pulmonary Hypertension

Interventions: Procedure: Red blood Cells auto-transfusion
Drug: Inhaled Nitric Oxide (iNO) administration

First Posted Date: 2012-02-08

Last Posted Date: 2017-05-22

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 14

Registration Number: NCT01529502

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy